Ret Proto-Oncogene anticorps (C-Term, Leu1027)
Aperçu rapide pour Ret Proto-Oncogene anticorps (C-Term, Leu1027) (ABIN2350377)
Antigène
Voir toutes Ret Proto-Oncogene (RET) AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- AA 1012-1042, C-Term, Leu1027
-
Réactivité croisée
- Humain
-
Réactivité croisée (Details)
- Calculated cross reactivity: Hu
-
Attributs du produit
- RET, CT (L1027) (RET, CDHF12, CDHR16, PTC, RET51, Proto-oncogene tyrosine-protein kinase receptor Ret, Cadherin family member 12, Proto-oncogene c-Ret, Soluble RET kinase fragment, Extracellular cell-membrane anchored RET cadherin 120kD fragment)
-
Purification
- Purified by Ammonium Sulfate Precipitation.
-
Immunogène
- KLH-conjugated synthetic peptide mapping to a fragment of residues within amino acids 1012-1042 in the C-terminal region of Human RET UniProt Accession #P07949.
-
Isotype
- IgG
-
-
-
-
Indications d'application
- Optimal working conditions should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Supplied as a liquid in PBS, pH 7.2, 0.09 % sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C
-
Stockage commentaire
- -20°C
-
-
- Ret Proto-Oncogene (RET)
-
Autre désignation
- RET
-
UniProt
- P07949
-
Pathways
- Signalisation RTK, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation
Antigène
-